Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza | Zendy

Francisco Bautista | Zendy; Dan Engelhard | Zendy; Carmelo Rizzari | Zendy; Margarita Baka | Zendy; Jesús SaavedraLozano | Zendy; Eduardo LópezMedina | Zendy; Clare NasmythMiller | Zendy; Jules HernándezSánchez | Zendy; Stefan Sturm | Zendy

Open Access

Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza

Author(s) -

Francisco Bautista,

Dan Engelhard,

Carmelo Rizzari,

Margarita Baka,

Jesús SaavedraLozano,

Eduardo LópezMedina,

Clare NasmythMiller,

Jules HernándezSánchez,

Stefan Sturm

Publication year - 2019

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofz430

Subject(s) - medicine , oseltamivir , pharmacokinetics , pharmacodynamics , pharmacology , covid-19 , disease , infectious disease (medical specialty)

This randomized phase 1b study evaluated the pharmacokinetics/pharmacodynamics of conventional-dose (30-75 mg twice daily [BID]) vs triple-dose (90-225 mg BID; weight-adjusted) oseltamivir for treatment of influenza in severely immunocompromised children <13 years. Oseltamivir carboxylate (OC) C and AUC were ~2-fold higher with triple-dose vs conventional-dose oseltamivir. Increased dose/exposure of oseltamivir/OC did not improve virological outcomes or reduce viral resistance. Median time to cessation of viral shedding was similar with triple-dose and conventional-dose oseltamivir (150.7 vs 157.1 hours, respectively); median time to alleviation of baseline fever was longer with conventional-dose oseltamivir (28.4 vs 11.3 hours). No new safety signals were identified.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research